Boehringer Ingelheim significantly expands its supply center for China

Boehringer IngelheimBoehringer Ingelheim intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai into a strategically important supply center for China. The goal of this project is to bring more health to more patients and to continuously improve Boehringer Ingelheim's product competitiveness and enlarge its market share.

With the expansion until end of 2013, the number of employees will rise significantly from 240 today to 400, the production capacity will be doubled.

"We want to expand our Zhangjiang plant, primarily to meet the demand for more health in China. It also shows our continuous commitment to China and specifically Shanghai", said Professor Dr Wolfram Carius, responsible for the Corporate Board Division Operations and Human Resources. "Our vision is to transform our Shanghai plant into a launch site in Boehringer Ingelheim's global Operations network."

The project intends to build a modular and lean manufacturing facility on the current production site. It will be able to produce marketed products and new pipeline products. The objective to have world-class production through a lean manufacturing approach will be supported by the optimisation of material flow and by our highly qualified employees.

In the first phase, which will be completed by the end of December 2013, a packaging center for ampoules and solids and a new automatic warehouse will be constructed. Furthermore, a new laboratory building for development activities will be set up on the site. In the second phase, to be concluded until the end of 2014, the existing solids manufacturing facility will be revamped and upgraded with new technologies.

The pharmaceutical industry is currently in the focus of Shanghai's economic strategy. Boehringer Ingelheim China’s strategy is in tune with the economic structure transformation advocated by the government and will lead the company into a new phase of development. "We are committed to meeting the growing demand of China's pharmaceutical market and to bringing more health to patients and their families", said David Preston, Chief Executive Officer of Boehringer Ingelheim China.

Since it entered the Chinese market in 1994, Boehringer Ingelheim has expanded its product range to cover respiratory, cardiovascular, central nervous system and other important therapeutic areas. In the forthcoming years, the company will continue to expand, including the therapeutic areas diabetes, oncology and stroke prevention.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...